YTS109 cell therapy for hard-to-treat autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new cell therapy (YTS109) for people with autoimmune hemolytic anemia (AIHA) that has not responded to at least three prior treatments. The goal is to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have been diagnosed with autoimmune hemolytic anemia (AIHA) or Evans syndrome.
- Your disease has not improved or you could not tolerate at least three prior treatments (including steroids and rituximab, plus another treatment like cyclosporine or splenectomy).
- Your hemoglobin level is below 100 g/L.
- Your liver and kidney function are adequate (ALT/AST up to 3 times normal, creatinine clearance at least 60 ml/min, blood oxygen at least 92%).
- You are willing to use contraception if you could become pregnant, and you agree to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can help control the disease when other options have failed.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests a new type of cell therapy (IASO206) for patients whose autoimmune hemolytic anemia (a condition where the body attacks its own red blood cells) has not responded to standard treatments. The therapy is designed to target and control the immune cells causing the problem.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.